A Global Disease,
A Pioneering Treatment

NASH: A Life-Threatening Epidemic
NASH (non-alcoholic steatohepatitis) is a complex liver disease that affects tens of millions of people around the world and can lead to liver failure, liver cancer and death.

A New Medicine To Restore Liver Health

Efruxifermin: Restoring Metabolic Balance to Improve Overall Health
Efruxifermin (EFX), formerly AKR-001 is designed to confront NASH holistically, leveraging the whole body to reduce liver fat, in turn reducing inflammation in the liver and ultimately inhibiting the deposition of collagen and reversing fibrosis. Our Phase 2a clinical trial in NASH patients, the BALANCED study, in which treated patients showed significant improvements in liver fat and histology, increased our confidence in EFX’s potential to become a foundational NASH monotherapy.